Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) kicked off on Monday, down -6.25% from the previous trading day, before settling in for the closing price of $2.08. Over the past 52 weeks, LXRX has traded in a range of $0.92-$3.73.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 186.21% over the past five years. While this was happening, its average annual earnings per share was recorded 14.05%. With a float of $349.07 million, this company’s outstanding shares have now reached $361.49 million.
Let’s look at the performance matrix of the company that is accounted for 285 employees. In terms of profitability, gross margin is 80.66%, operating margin of -5412.11%, and the pretax margin is -5509.34%.
Lexicon Pharmaceuticals Inc (LXRX) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Lexicon Pharmaceuticals Inc is 3.44%, while institutional ownership is 76.87%. The most recent insider transaction that took place on Aug 15 ’24, was worth 480,000. Before that another transaction happened on Nov 16 ’23, when Company’s Chief Executive Officer bought 90,000 for $1.05, making the entire transaction worth $94,797. This insider now owns 914,359 shares in total.
Lexicon Pharmaceuticals Inc (LXRX) Latest Financial update
In the latest quarterly report, which was put into the public domain on 6/30/2024, the organization reported -0.21 earnings per share (EPS), higher than consensus estimate (set at -0.21) by 0. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.16 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 14.05% per share during the next fiscal year.
Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) Trading Performance Indicators
Take a look at Lexicon Pharmaceuticals Inc’s (LXRX) current performance indicators. Last quarter, stock had a quick ratio of 11.49. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 193.66.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.77, a number that is poised to hit -0.16 in the next quarter and is forecasted to reach -0.59 in one year’s time.
Technical Analysis of Lexicon Pharmaceuticals Inc (LXRX)
Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) saw its 5-day average volume 3.52 million, a positive change from its year-to-date volume of 3.38 million. As of the previous 9 days, the stock’s Stochastic %D was 74.40%. Additionally, its Average True Range was 0.11.
During the past 100 days, Lexicon Pharmaceuticals Inc’s (LXRX) raw stochastic average was set at 47.92%, which indicates a significant decrease from 64.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 52.13% in the past 14 days, which was lower than the 77.76% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.70, while its 200-day Moving Average is $1.90. Nevertheless, the first resistance level for the watch stands at $2.04 in the near term. At $2.12, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.17. If the price goes on to break the first support level at $1.90, it is likely to go to the next support level at $1.85. The third support level lies at $1.77 if the price breaches the second support level.
Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) Key Stats
The company with the Market Capitalisation of 704.91 million has total of 246,237K Shares Outstanding. Its annual sales at the moment are 1,200 K in contrast with the sum of -177,120 K annual income. Company’s last quarter sales were recorded 1,650 K and last quarter income was -53,430 K.
